Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05467605
Other study ID # probiotics in pediatric sepsis
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 22, 2022
Est. completion date February 5, 2023

Study information

Verified date February 2023
Source Cairo University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To assess the effect of probiotics on cytokine's level(interleukin 6 and Transforming growth factor-β1)in children admitted to PICU with sepsis.


Description:

Sepsis, defined as an infection with deregulated host response leading to life-threatening organ dysfunction. Historically, the term sepsis has been used to characterize life-threatening infections usually caused by bacterial pathogens if untreated progress to shock and death, It contributes to 19% of all deaths globally, with the highest age-specific incidence in children younger than 5 years of age. Pediatric sepsis resulted in 0.7% of all hospital encounters. Epidemiologic studies found an incidence of pediatric sepsis in up to 8% of all pediatric intensive care unit (PICU) admissions, contributing to 1in 4 deaths in PICUs. Despite many advances in diagnosis and management, sepsis is associated with significant morbidity and mortality in pediatric population. The pathophysiology of systemic inflammatory response syndrome (SIRS)and sepsis is characterized by hyperactive and deregulated endogenous inflammatory mediators in a sequential manner resulting in a cytokine cascade. Cytokines are regulators of the immune response to infection and play a key role in regulating inflammation and trauma. There are two types of cytokines. Pro-inflammatory cytokines and anti-inflammatory cytokines. Pro-inflammatory cytokines(tumor necrosis factor [TNF]-α, interferon-γ, interleukin[IL]-1α, IL-1β, IL-6, IL-8, IL-12, IL-17) are important for initiation of an effective inflammatory response against pathogens, whereas their excess production can lead to multiple organ dysfunction syndrome (MODS) and mortality, on the other side, anti-inflammatory cytokines (IL-4, IL-10, IL-13,transforming growth factor [TGF]-β) are required for controlling and down-regulating the inflammatory response and if severe can lead to depression of the immune system. The levels of these cytokines rise within few hours of onset of sepsis and remain elevated for days together depending on severity and duration of sepsis, baseline host factors, timing of sampling relative to onset of sepsis/septic shock, and inter-individual variation. The gastrointestinal system seems to play a key role in the pathogenesis MODS owing to a breakdown of intestinal barrier function and increased translocation of bacteria and bacterial components into the systemic circulation. During critical illness, alterations occur in gut micro flora owing to change in circulating stress hormones, gut ischemia, immune suppression, the use of antibiotics, and lack of nutrients due to delay in starting enteral feeding. Probiotics are living micro-organisms that, when administered in adequate amounts, can help maintain the integrity of the intestinal barrier function by modulating the immune response. Such administration has been included in the management of critically ill patients as a therapeutic approach. Various studies highlighted that probiotics can modulate intestinal micro biota by colonizing human GIT, preventing overgrowth of pathogens, normalizing altered intestinal flora, reducing bacterial translocation, influencing immune system, and balancing control of pro-inflammatory and anti-inflammatory Cytokines.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date February 5, 2023
Est. primary completion date January 20, 2023
Accepts healthy volunteers No
Gender All
Age group 30 Days to 14 Years
Eligibility Inclusion Criteria: - The study will include children admitted to PICU with sepsis defined as presence of suspected or proven infection with two or more criteria for systemic inflammatory response syndrome (SIRS) Exclusion Criteria: - Children having contraindications to start enteral feeding. - Children with known chronic gastrointestinal illness. - Children known with immunodeficiency. - Children on prior steroids or immunotherapy.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
probiotics( Lactobacillus acidophilus, lactobacillus delbruekii and lactobacillus fermentum 10 billions),
therapeutic intervention, Children will be randomized into two groups using sealed envelopes on admission after meeting inclusion criteria, group ONE will receive multi strain probiotic product which contains(Lactobacillus acidophilus, lactobacillus delbruekii and lactobacillus fermentum 10 billions),
Other:
maltose dissolved in distilled water
the other group placebo (GROUP TWO ) will receive maltose dissolved in 10 ml distilled water .

Locations

Country Name City State
Egypt Cairo University Faculty of Medicine Cairo

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

References & Publications (2)

Angurana SK, Bansal A, Singhi S, Aggarwal R, Jayashree M, Salaria M, Mangat NK. Evaluation of Effect of Probiotics on Cytokine Levels in Critically Ill Children With Severe Sepsis: A Double-Blind, Placebo-Controlled Trial. Crit Care Med. 2018 Oct;46(10):1 — View Citation

Chaudhry H, Zhou J, Zhong Y, Ali MM, McGuire F, Nagarkatti PS, Nagarkatti M. Role of cytokines as a double-edged sword in sepsis. In Vivo. 2013 Nov-Dec;27(6):669-84. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary 1- To assess the effect of probiotics on cytokine levels(interleukin 6 and Transforming growth factor-ß1) in probiotic group To assess the effect of probiotics on cytokine levels(interleukin 6 and Transforming growth factor-ß1) in probiotic group and To assess the change on cytokine levels (interleukin 6 and Transforming growth factor-ß1) from day 1 to 7 in critically ill children with sepsis in two groups. one week
Secondary assessment of other sepsis parameters Assessment of other sepsis parameters like C-reactive protein ( CRP ) level in relation to prognosis of sepsis in the two groups. up to 2 weeks
Secondary assessment of patient general condition during pediatric intensive care admission The duration of ventilation, will be assessed in the two groups. through admission till discharge from PICU up to one month
Secondary assessment of patient general condition during pediatric intensive care admission length of stay in the PICU, will be assessed in the two groups. through admission till discharge from PICU up to one month
See also
  Status Clinical Trial Phase
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Recruiting NCT04796636 - High-dose Intravenous Vitamin C in Patients With Septic Shock Phase 1
Terminated NCT04134624 - EMS Prehospital Blood Culture Collection and Antibiotic Administration: A Two-Phase Pilot Project to Reduce Mortality in Patients With Severe Sepsis and Septic Shock N/A
Withdrawn NCT04821414 - Effects of IL-1β and Its Receptor Antagonists in the Treatment of Severe Infection and Inflammatory Storm in Children
Recruiting NCT05357339 - Microcirculation Properties of Albumin for Fluid Resuscitation in Septic Shock N/A
Recruiting NCT06178822 - Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room
Completed NCT04833621 - Is NMES Treatment in Sepsis/ Septic Shock Patients Protective in Development of ICU-AW? N/A
Not yet recruiting NCT04105400 - Procalcitonin in Diagnosis of Sepsis in Critically Ill Patient
Completed NCT04459572 - As an Early Indicator Biomarker of Prognosis and Mortality in Children With Sepsis and Septic Shock: suPAR N/A
Completed NCT04508296 - The Effect pf Goal-directed De-escalation in ARDS on Organ Function and Mortality N/A
Recruiting NCT03685214 - Comparison of Balanced Crystalloids and Normal Saline in Septic Patients N/A
Not yet recruiting NCT04850456 - Treatment Strategy of Human Gamma Globulin on the Therapy for Intensively Ill Children With Inflammatory Storm
Completed NCT04747795 - Early Administration of Vitamin C in Patients With Sepsis or Septic Shock in Emergency Departments Phase 3
Terminated NCT03821038 - Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients Phase 2
Completed NCT05246969 - Detecting Sepsis in Patients With Severe Subarachnoideal Hemorrhage
Recruiting NCT05442710 - Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy Phase 2
Completed NCT03974386 - Effects of Endotoxin Absorption and Cytokine Removal Hemofilter on Severe Septic Shock N/A
Recruiting NCT04203979 - Sepsis: From Syndrome to Personalized Care
Not yet recruiting NCT03367026 - Reducing Elevated Heart Rate in Patients With Severe Sepsis by Ivabradine N/A
Recruiting NCT03244293 - Bispectral Index (BIS) for Classification of Procalcitonin (PCT) Sepsis Grades in Critically Ill Patients With Sepsis